Would you add immunotherapy to FOLFOX if the patient is not a FLOT candidate for neoadjuvant gastric cancer, extrapolating data from the MATTERHORN study?

While it is always somewhat perilous to extrapolate from a proper study to lesser situations, this seems quite reasonable. It seems highly unlikely that the removal of Taxotere from a fluoropyrimidine-oxaliplatin-based regimen would render immunotherapy less effective in gastric cancer. In the MATTE...

It is important to remember the context of MATTERHORN compared to trials such as KEYNOTE-585, where immunotherapy was used with predominantly different chemotherapy regimens. We cannot draw the same conclusions about pathological complete response and overall survival with FOLFOX that we can with FL...

Add an IO to the FOLFOX regimen in the neoadjuvant chemotherapy for gastric cancer.